Buy Veracyte

Logo for stock VCYT (Veracyte)

Amount

£
GBP

Latest price

$27.37
(£1.00 = $1.343)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$2.153B

P/E ratio

81.89

EPS

$0.334

Beta

2.05

Dividend rate

N/A

Dividend yield

N/A

About

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

CEO

Mr. Marc A. Stapley

Employees

824

Sector

Health

Company HQ

SOUTH SAN FRANCISCO, United States of America

News

Logo for news article #0 (Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript)

Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript

Veracyte, Inc. (NASDAQ:VCYT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Marc A. Stapley - CEO & Director Phillip G.

Seeking Alpha

August 07, 2025

Logo for news article #1 (Veracyte (VCYT) Q2 Revenue Jumps 14%)

Veracyte (VCYT) Q2 Revenue Jumps 14%

Veracyte (VCYT) Q2 Revenue Jumps 14%

The Motley Fool

August 07, 2025

Logo for news article #2 (Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates)

Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates

Veracyte (VCYT) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to earnings of $0.3 per share a year ago.

Zacks Investment Research

August 06, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies is an Introducer Appointed Representative of Quint Group Limited and not a lender. Quint Group Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 669450). Monevo Limited is an Appointed Representative of TransUnion International UK Limited. TransUnion is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 737740). Emma Technologies introduces customers first to Quint Group Limited, as a licensed credit broker, who then refers on to Monevo Limited.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.